Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Steroids for Enuresis with OSA
NCT01861145Phase 4Withdrawn
- Sponsor
- University of Alberta
- Start
- May 2013
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of mometasone furoate nasal spray in enuresis and obstructive sleep apnea (OSA), sponsored by University of Alberta. Primary endpoint: Degree of improvement in enuresis at 3 months. Planned start May 2013; status: withdrawn.
02
Drugs
mometasone furoate nasal spray
03
Conditions
enuresisobstructive sleep apnea (OSA)
Beyond the preview
Go deeper on NCT01861145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01861145.